The bacterium Mycobacterium tuberculosis (Mtb) causes tuberculosis and is responsible for more human mortality than any other single pathogen 1 . Progression to active disease occurs in only a fraction of infected individuals and is predicted by an elevated type I interferon (IFN) response 2-7 . Whether or how IFNs mediate susceptibility to Mtb has been difficult to study due to a lack of suitable mouse models 6-11 . Here, we examined B6.Sst1 S congenic mice that carry the 'susceptible' allele of the Sst1 locus that results in exacerbated Mtb disease 12-14 . We found that enhanced production of type I IFNs was responsible for the susceptibility of B6.Sst1 S mice to Mtb. Type I IFNs affect the expression of hundreds of genes, several of which have previously been implicated in susceptibility to bacterial infections 6,7,15-18 . Nevertheless, we found that heterozygous deficiency in just a single IFN target gene, Il1rn, which encodes interleukin-1 receptor antagonist (IL-1Ra), is sufficient to reverse IFN-driven susceptibility to Mtb in B6.Sst1 S mice. In addition, antibody-mediated neutralization of IL-1Ra provided therapeutic benefit to Mtb-infected B6.Sst1 S mice. Our results illustrate the value of the B6.Sst1 S mouse to model IFN-driven susceptibility to Mtb, and demonstrate that IL-1Ra is an important mediator of type I IFNdriven susceptibility to Mtb infections in vivo.
by which type I IFNs mediate susceptibility to active TB, with the hope that this knowledge could be exploited to develop interventions. Mechanistic studies and initial trials of possible therapeutics require a robust animal model. However, the most commonly used animal model, the C57BL/6 (B6) mouse, does not robustly recapitulate the IFN-driven TB susceptibility that appears to occur in humans. B6.Ifnar −/− mice show mild resistance to Mtb in the spleen and variable but modest effects in the lungs [8] [9] [10] [11] 15 . Another model of IFN-driven susceptibility involves treatment of Mtbinfected B6 mice with poly-IC, a potent inducer of type I IFNs 9, 16 . Such treatment dramatically increases susceptibility to Mtb in an Ifnar-dependent manner 9, 16 , but because the IFN is induced artificially via signalling pathways such as TLR3 or MDA5 that may not be engaged by Mtb itself, it is unclear whether poly-IC treatment mimics the course of IFN-driven disease in humans. The 129 mouse strain shows clear IFN-driven susceptibility to Mtb 26 , but there are limited tools on this genetic background.
As an alternative approach, we turned to a previously described congenic mouse strain, B6.Sst1 S , that carries the 10.7 Mb 'super susceptibility to tuberculosis 1' region of mouse chromosome 1 from C3HeB/FeJ mice on an otherwise B6 genetic background 12, 13 . B6.Sst1 S mice exhibit marked susceptibility to aerosol Mtb infection 12, 13 , although how the Sst1 S locus confers susceptibility remains incompletely understood. Recent work has established that bone marrow macrophages (BMMs) from B6.Sst1 S mice exhibit an enhanced type I IFN response 29, 30 , as we confirm (Extended Data Fig. 1 ). In addition, we found that infected B6.Sst1 S lungs exhibited higher levels of Ifnb transcripts as compared to B6 (Fig. 1a ). To investigate whether this enhanced type I IFN signalling causes the susceptibility of B6.Sst1 S mice to Mtb, we treated Mtb-infected mice with an IFNAR1-blocking antibody 31 to inhibit type I IFN signalling. B6.Sst1 S mice treated with the IFNAR1-blocking antibody showed significantly decreased bacterial burdens compared to those that received only an isotype control antibody (Fig. 1b ). To provide genetic confirmation of this result, we crossed B6.Sst1 S mice to B6.Ifnar −/− mice. Ifnar deficiency largely reversed the enhanced susceptibility of B6.Sst1 S mice to Mtb infection. At 25 days postinfection, the lung bacterial burdens of B6.Sst1 S Ifnar −/− mice were significantly lower than those of B6.Sst1 S mice, and were similar to those of B6 mice (Fig. 1c ). Infected B6.Sst1 S Ifnar −/− mice also survived significantly longer than B6.Sst1 S mice (Fig. 1d ), although there are also clearly Ifnar-independent effects of the Sst1 S locus that act at later time points. By contrast, and consistent with previous Letters Nature Microbiology reports 8, 10, 11 , Ifnar deficiency had little or no effect on Mtb disease in wild-type B6 mice. Recent data have suggested that the host protein STING is required for IFN induction to Mtb [32] [33] [34] [35] [36] [37] . However, crossing B6.Sst1 S mice to STING-deficient Sting gt/gt mice did not significantly reduce bacterial burdens at day-25 compared to B6.Sst1 S mice (Extended Data Fig. 2a ). The B6.Sst1 S Sting gt/gt mice did show a slight improvement in survival not seen in the B6 genetic background 36 (Extended Data Fig. 2b ). Overall, our data demonstrate that the Sst1 S locus acts directly or indirectly to increase type I IFN signalling in vivo and thereby exacerbate Mtb infection, particularly during the early phases of infection.
Type I IFN negatively regulates anti-bacterial immune responses via multiple mechanisms 6, 7, 18 , including through increased IL-10 levels [15] [16] [17] , decreased IFNγ signalling 38, 39 , induction of cholesterol 25-hydroxylase (Ch25h) 40 and/or decreased IL-1 levels 15, 16, 41 . We did not observe significant differences between B6 or B6.Sst1 S mice in IL-10 or IFNγ levels in the lung during Mtb infection (Extended Data Fig. 3a,b ). Crossing B6.Sst1 S mice to B6.Ch25h −/− mice did not alter day-25 lung bacterial burdens (Extended Data Fig. 3c ). Moreover, despite clear evidence that type I IFN and IL-1 counter-regulate each other 15, 16, 41, 42 , the Sst1 S locus did not appear to decrease the levels of IL-1 in vivo; in fact, we unexpectedly observed higher levels of both IL-1α and IL-1β in the lungs of B6.Sst1 S mice at 25 days post-infection as compared to B6 mice ( Fig. 2a,b , associated colonyforming units (CFUs) in Extended Data Fig. 3d ). Other inflammatory mediators, including TNF and CXCL1, were similarly elevated in the B6.Sst1 S mice (Extended Data Fig. 3e ,f) as was the frequency of CD11b + Ly6G + cells (neutrophils) in the lungs (Extended Data Fig. 3g ). The elevated inflammation in B6.Sst1 S mice was a direct or indirect consequence of elevated type I IFNs, as inflammatory cytokines and neutrophils were reduced in B6.Sst1 S Ifnar −/− mice ( Fig. 2a,b and Extended Data Fig. 3a ,b,e-g).
We reasoned that the high levels of IL-1α/β in B6.Sst1 S mice may be a consequence of the higher bacterial burdens in these mice, or alternatively, may be causing increased bacterial replication via induction of a pro-bacterial inflammatory milieu, as previously proposed 43, 44 . To distinguish these possibilities, we inhibited IL-1 signalling in vivo using an anti-IL-1R1 blocking antibody 45 ( Fig. 2c and Extended Data Fig. 4a ). Both B6 and B6.Sst1 S mice treated with IL-1R1 blocking antibody exhibited increased B6 
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bacterial burdens compared to mice treated with an isotype control antibody. These results confirm previous evidence that IL-1 is protective in B6 mice [46] [47] [48] [49] [50] [51] [52] , and extend this observation to B6.Sst1 S mice as well. Thus, elevated IL-1 levels do not explain the exacerbated infections of B6.Sst1 S mice. Instead, it appears that elevated IL-1 levels are a consequence of increased bacterial burdens in these mice. Although IL-1 is clearly protective during Mtb infection of B6 mice, the elevated levels of IL-1α/β proteins seen in B6.Sst1 S mice for some reason fail to control Mtb. Type I IFNs induce the expression of hundreds of target genes. However, given that IL-1 signalling is essential for resistance to Mtb 46-52 , we were particularly interested in Il1rn, which encodes the secreted IL-1Ra (ref. 53 ). IL-1Ra binds to IL-1R1 without signalling and blocks binding of IL-1α/β 54 (Fig. 3a ). Il1rn is induced during Mtb infection 15, 16 and by type I IFN signalling 55, 56 . As expected, B6.Sst1 S BMMs strongly upregulated Il1rn in an Ifnardependent manner when stimulated with TNF ( Fig. 3b) . Similarly, Mtb-infected B6.Sst1 S mice had higher levels of IL-1Ra protein in their lungs, as compared to B6 or B6.Sst1 S Ifnar −/− mice ( Fig. 3c and Extended Data Fig. 4b ). These results raised the possibility that the high IL-1 protein levels in B6.Sst1 S mice are inadequate to protect against infection because of a block in IL-1 signalling.
To assess the levels of functional IL-1 signalling in the lungs of infected mice, we employed an IL-1 reporter bioassay to measure IL-1 activity in cell-free supernatant of dissociated lungs. Despite higher levels of IL-1 proteins, lungs from infected B6.Sst1 S mice appeared to have generally less functional IL-1 signalling capacity as compared with B6 mice ( Fig. 3d and Extended Data Fig. 4c ). The lower levels of IL-1 signalling seen in B6.Sst1 S mice were reversed in B6.Sst1 S Ifnar −/− mice (Fig. 3d ). The reporter appeared to be a reliable indicator of functional IL-1, as responses in the bioassay were blocked by anti-IL-1R1 antibody (Extended Data Fig. 4c ). These results underline the importance of measuring IL-1 activity versus merely assessing the levels of IL-1 proteins. However, we noted significant variability in the measurable IL-1 activity in the lungs of Mtb-infected mice. In fact, the lungs of some B6.Sst1 S mice exhibited elevated, rather than reduced, IL-1 activity (for example, 3 of 17 mice shown in Fig. 3d ). In addition, in infections with higher initial doses, we failed to detect a difference in the IL-1 activity in the lungs of B6.Sst1 S versus B6 mice (an example is shown in Extended Data Fig. 4d ). Conversely, the susceptibility of B6.Sst1 S mice is highly consistent (Figs. 1c and 2c and Extended Data Figs. 2a, 3c,d and 4a). Thus, we hypothesized that low IL-1 signalling may be only a transient phenotype in B6.Sst1 S mice.
IL-1β
Cntrl Anti-IL-1R1 Cntrl Cntrl To address this possibility, we assessed the timing of IL-1 activity in the lung by performing a time course experiment (Extended Data Fig. 4e ). We found that at 14 days post-infection, IL-1 activity measurable by bioassay was low in all strains. At 25 days post-infection, there was marked variability in the measurable IL-1 responses of B6.Sst1 S mice: some mice exhibited the expected defect in IL-1 activity as compared to B6 or B6.Sst1 S Ifnar −/− mice, whereas others were already exhibiting high IL-1 activity levels. By 36 days post-infection, all mice exhibited high IL-1 activity regardless of genotype. Thus, it appears that once the susceptible phenotype of B6.Sst1 S mice manifests, and CFU levels rise, the level of functional IL-1 increases concordantly. Interestingly, this late rise in IL-1 activity appears insufficient to protect the mice. It was previously reported that IL-1 acts at early time points after infection (that is, prior to day 15 post-infection 57 ). At early time points, when IL-1 may be acting locally at infection foci, the bioassay (performed on total lung) is unable to detect functional IL-1. Thus, we conclude that although specific infection conditions and assay time points can reveal a functional deficit in IL-1 signalling in B6.Sst1 S mice, our IL-1 bioassay is generally an insensitive tool for measuring protective IL-1 activity in vivo.
Given the above considerations, we sought genetic evidence to address whether excessive type I IFN signalling neutralizes IL-1 signalling via IL-1Ra in B6.Sst1 S mice during Mtb infection. Accordingly, we crossed B6.Sst1 S to Il1rn −/− mice 58 . Since uninfected Il1rn −/− mice exhibit signs of inflammatory disease due to dysregulated IL-1 signalling 54, 58, 59 , and because Il1rn +/mice have a partial decrease in IL-1Ra levels 58 , we generated both heterozygous B6.Sst1 S Il1rn +/and homozygous B6.Sst1 S Il1rn −/− mice. Both heterozygous and homozygous Il1rn deficiency protected B6.Sst1 S mice from Mtb ( Fig. 4a-d and Extended Data Fig. 5a ). In fact, bacterial burdens in B6.Sst1 S Il1rn −/− mice were even lower than those found in 'resistant' B6 mice ( Fig. 4a ). B6.Sst1 S Il1rn −/− mice survived only modestly longer than B6.Sst1 S mice (Fig. 4b ), but this was expected since even uninfected Il1rn −/− mice exhibit shortened lifespans due to spontaneous inflammatory disease 59 . Notably, a partial reduction in IL-1Ra levels in heterozygous B6.Sst1 S Il1rn +/mice was sufficient to almost entirely reverse the enhanced IFN-driven susceptibility of Sst1 S mice ( Fig. 4a-d ). In fact, the bacterial burdens, survival and body weights of B6.Sst1 S Il1rn +/mice resembled those of B6 mice (Fig. 4a-c and Extended Data Fig. 5a ). Histological samples of infected lungs showed significant reduction in lesion sizes in both B6.Sst1 S Il1rn +/and B6.Sst1 S Il1rn −/− mice compared to B6.Sst1 S (Fig. 4d ). Lungs of B6.Sst1 S Il1rn +/mice infected with a low dose of Mtb (~14 CFUs) had greater IL-1 bioactivity at day 21 than those of B6.Sst1 mice (Extended Data Fig. 5b ), but a difference in IL-1 activity was not detectable in mice infected with a higher dose (~55 CFUs) (Extended Data Fig. 5c ), again illustrating the limitations of the IL-1 bioassay as discussed above. Nevertheless, control of the infection in Il1rn-deficient mice depended on IL-1 receptor signalling, as B6.Sst1 S Il1rn +/or B6.Sst1 S Il1rn −/− mice treated with a blocking anti-IL-1R1 antibody 45 exhibited higher bacterial burdens than untreated mice (Extended Data Fig. 5e ). These data and the known biology of IL-1Ra strongly imply that protection afforded by the loss of IL-1Ra is mediated by enhanced IL-1 signalling, although it is formally possible that Il1rn deficiency protects the B6.Sst1 S mice via a mechanism unrelated to IL-1 and that neutralization of IL-1 signalling dominantly overcomes this protection. 
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Despite decreased bacterial burdens, the lungs of B6.Sst1 S Il1rn +/mice had similar levels of Ifnb or other IFN-induced transcripts to those of B6.Sst1 S mice (Extended Data Fig. 5d ). These results are consistent with a model in which IL-1Ra acts downstream of type I IFN signalling, and does not contribute to reducing Ifnb levels other than by reducing overall bacteria burden. 
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The dramatic protective effects of even partial reductions in IL-1Ra in B6.Sst1 S mice suggested that IL-1Ra might be a suitable target for host-directed therapy during Mtb infection. To test this, we treated infected B6.Sst1 S mice with an anti-IL-1Ra antibody 60 to block IL-1Ra and restore IL-1 signalling. B6.Sst1 S mice that received the antibody had significantly lower bacterial burdens in their lungs as compared to PBS-treated controls (Fig. 4e ). In addition, mice treated with anti-IL-1Ra antibody retained significantly more body weight than the controls (Fig. 4f ) and exhibited reduced lung lesions (Fig. 4g ), suggesting that the treatment did not cause detrimental inflammation. To determine whether IL-1Ra acts downstream of type I IFN signalling, we neutralized IL-1Ra in B6.Sst1 S Ifnar −/− mice (Extended Data Fig. 5f ). Bacterial burdens were similar between B6.Sst1 S Ifnar −/− mice treated with the anti-IL-1Ra antibody and control, consistent with the low expression of IL-1Ra in B6.Sst1 S Ifnar −/− mice (Fig. 3c) , whereas antibody-treated B6.Sst1 S mice exhibited reduced CFUs. Overall, these data indicate that genetic or antibody-mediated reduction of IL-1Ra can rescue the type I IFN-driven susceptibility to Mtb in B6.Sst1 S mice without overt detrimental immunopathology.
The Sst1 locus spans ~10 Mb and encodes ~50 genes. Collectively, our data indicate that in B6 (Sst1 R ) mice, the Sst1 locus acts directly or indirectly to repress type I IFN signalling, although the underlying molecular mechanism is unknown. Previously, Sst1 S mice were found to lack expression of Ipr1 (also called Sp110) and re-expression of B6-derived Ipr1 partially restores resistance to Mtb 12 . Thus, loss of Ipr1 may account for the Sst1 S phenotype, although this remains to be confirmed by the generation of B6.Ipr1 −/− mice. Polymorphisms in human SP110 are associated with TB disease in some but not all cohorts [61] [62] [63] [64] [65] [66] [67] [68] . Ipr1 is a member of the Sp100 family of transcriptional regulators that also includes Sp100, Sp140 and Aire. SP100 proteins contain chromatin-binding domains and regulate gene expression. It is tempting to speculate that IPR1 modulates the chromatin state of type I IFNs and/or IFN-induced genes, although future studies are necessary to establish the molecular basis of the Sst1 S phenotype.
There is increasing interest in developing host-directed therapeutics for Mtb 20 . Although such therapeutics have not yet proved to be curative, and are unlikely to replace antibiotics, they may be advantageous in specific scenarios. For example, host-directed therapy could serve as an adjunct to antibiotics for multi-drugor extensively drug-resistant TB, which are associated with high mortality rates 69, 70 . If indeed type I IFNs exacerbate TB disease in humans, then a host-directed therapy targeting IL-1Ra, alone or in combination with other host-directed interventions 16 , might represent a promising approach. Targeting IL-1Ra may be preferable to blockade of upstream type I IFNs, which might exacerbate viral infections. Regardless, our results show that the B6.Sst1 S mouse represents a useful model that permits genetic dissection of the molecular mechanisms underlying IFN-driven TB disease.
Methods
Mice. All mice were specific pathogen-free, maintained under a 12-h light/dark cycle (7:00 to 19:00), and given a standard chow diet (Harlan irradiated laboratory animal diet) ad libitum. Within each experiment, mice of all genotypes were agematched at 6-10 weeks old at the beginning of infections. Whenever possible, we used comparable numbers of each sex across all genotypes in an experiment. Mouse work was not subjected to randomization or data blinding. C57BL/6J (B6), B6.129S-Il1rn tm1Dih /J (Il1rn −/− , Jax no. 004754) 58 , B6(Cg)-Ifnar1 tm1.2Ees /J (Ifnar −/− , Jax no. 028288) and B6.129S6-Ch25htm1Rus /J (Ch25h −/− , Jax no. 016263) 71 mice were originally purchased from Jackson Laboratories and subsequently bred at UC Berkeley. B6J. C3-Sst1 C3HeB/FeJKrmn mice (referred to as B6.Sst1 S throughout) were from the colony of I. Kramnik at Boston University and then transferred to UC Berkeley. Sting gt/gt mice were previously described 72 . All animals used in experiments were bred in-house unless otherwise noted in the figure legends. All animal experiments complied with the regulatory standards of, and were approved by, the University of California Berkeley Institutional Animal Care and Use Committee.
Mtb infections.
Mtb strain Erdman (gift from S.A. Stanley) was used for all infections. Frozen stocks of this wild-type strain were made from a single culture and used for all experiments. Cultures for infection were grown in Middlebrook 7H9 liquid medium supplemented with 10% albumin-dextrose-saline, 0.4% glycerol and 0.05% Tween-80 for 5 days at 37 °C. Mice were aerosol-infected using an inhalation exposure system (Glas-Col). Cultures were diluted to deliver ~20 to 100 bacteria per mouse as measured by CFUs in the lungs 1 day following infection, depending on the experiment. Mice were euthanized at various days post-infection as indicated in the figure legends to measure CFUs and/or cytokines. All but one lung lobe was homogenized in PBS plus 0.05% Tween-80 or processed for cytokines (see below), and serial dilutions were plated on 7H11 plates supplemented with 10% oleic acid, albumin, dextrose, catalase (OADC) and 0.5% glycerol. CFUs were counted 21-25 days after plating. The remaining lobe was used for histology or for RNA extraction. For histology, the sample was fixed in 10% formalin for at least 48 h and then stored in 70% ethanol. Samples were sent to Histowiz Inc. for embedding in wax, sectioning and H&E staining. Samples for RNA were preserved with RNAlater solution (Invitrogen) according to the manufacturer's specifications for later processing.
Cytokine measurements. Cell-free lung homogenates were generated as previously described 47 . Briefly, lungs were dissociated through 100 μm Falcon cell strainers in sterile PBS with 1% fetal bovine serum (FBS) and Pierce Protease Inhibitor EDTA-free (Thermo Fisher). An aliquot was removed for measuring CFUs by plating as described above. Cells and debris were then removed by, first, a low-speed centrifugation (approximately 300g) and then a high-speed centrifugation (approximately 2,000g), and the resulting cell-free homogenate was filtered twice with 0.2 μm filters to remove all Mtb for work outside biosafety level 3 (BSL3) conditions. All homogenates were aliquoted, flash-frozen in liquid nitrogen and stored at -80 °C. Each aliquot was thawed a maximum of twice to avoid potential artefacts due to repeated freeze-thaw cycles. All cytokines except IL-10 and IL-1Ra were measured using the Cytometric Bead Assay (BD Biosciences) according to the manufacturer's protocols. Results were collected using BD LSRFortessa (BD Biosciences) and analysed using FCAP Array v3.0. IL-10 levels were measured using Mouse IL-10 ELISA Ready-SET-Go! (2nd Generation, eBioscience). IL-1Ra levels were measured by enzyme-linked immunosorbent assay (ELISA) using the mouse IL-1ra/IL-1F3 Quantikine ELISA Kit (R&D Systems) according to the manufacturer's protocols.
IL-1 bioactivity reporter assay.
Mice infected with a low dose of Mtb (see text for discussion) were used to prepare cell-free lung homogenates. Samples were assayed using HEK-Blue IL-1R cells (InvivoGen). Cells were authenticated and tested for mycoplasma by the manufacturer. All experiments used cells under 6 passages from the original stock. A total of 3.75 × 10 4 cells per well were plated in 96-well plates, and allowed to adhere overnight in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U ml −1 streptomycin and 100 μg ml −1 penicillin. Over-confluence decreases the accuracy of the assay. Reporter cells were treated overnight with 100 μl of sample (consisting of 50 μl of cell-free lung homogenates and 50 μl of media), or recombinant mouse IL-1β (R&D systems 401-ML-005) mixed with 100 μl of media (to generate a standard curve). Assays were developed using QUANTI-Blue (InvivoGen) according to the manufacturer's protocols.
Flow cytometry. Lungs were perfused with 10 ml of cold PBS and dissociated through 40 μm cell strainers. Aliquots were removed for quantifying CFUs. Cells were washed and stained with fixable viability dye (Thermo Fisher 65-0865-14). An aliquot of cells from each sample was removed and mixed with counting beads (Thermo Fisher C36950) for later enumeration. The rest of the cells were incubated with anti-mouse CD16/CD32 monoclonal antibody to block Fc receptors (Thermo Fisher 14-0161-81), and then with antibodies for surface staining. The following antigens were stained for: CD45 (30-F11, Biolegend 103107), CD11b (M1/70, Thermo Fisher 48-0112-82), CD11c (N418, Biolegend 117335), Ly6G (1A8, BD Biosciences 740554), Ly6C (HK1.4, Thermo Fisher 17-5932-80), CD24 (M1/69, BD Bioscience 564664), MHC II (M5/114.15.2, Biolegend 107625), SiglecF (E50-2440, BD Biosciences 562680). Cells were fixed with fixation buffer (BD Biosciences 554714) for at least 1 h at room temperature and stored in PBS with 1% FBS and 2 mM EDTA overnight at 4 °C in the dark. Data were acquired on a BD Fortessa X-20 flow cytometer and analysed with FlowJo v10.
BMMs and TNF treatment. Bone marrow was collected from mouse femurs and tibiae, and cells were differentiated by culture on non-tissue-culture-treated plates in RPMI supplemented with supernatant from 3T3-MCSF cells (gift from B. Beutler), 10% FBS, 2 mM glutamine, 100 U ml −1 streptomycin and 100 μg ml −1 penicillin in a humidified incubator (37 °C, 5% CO 2 ). BMMs were collected 6 days after plating and frozen in 95% FBS and 5% dimethylsulfoxide. For in vitro experiments, BMMs were thawed into media as described above for 4 h in a humidified 37 °C incubator. Adherent cells were washed with PBS, counted and replated at 1.2 × 10 6 -1.5 × 10 6 cells per well in a TC-treated 6-well plate. Cells were treated with 10 ng ml −1 recombinant mouse TNFα (410-TRNC-010, R&D Systems) diluted in the media as described above.
Quantitative RT-PCR. Total RNA from BMMs was extracted using the RNeasy total RNA kit (Qiagen) according to the manufacturer's specifications. Total lung RNA was extracted by homogenizing the tissue in TRIzol reagent (Life Technologies) and then mixing thoroughly with chloroform, both carried out under BSL3 conditions. Samples were then removed from the BSL3 facility and transferred to fresh tubes under BSL2 conditions. The aqueous phase was separated by centrifugation and RNA was further purified using an RNeasy total RNA kit (Qiagen). Equal amounts of RNA from each sample were treated with DNase (RQ1, Promega) and complementary DNA was made using Superscript III (Invitrogen). cDNA reactions were primed with poly(dT) for the measurement of mature transcripts. Quantitative PCR was performed using the QuantiStudio 5 Real-Time PCR System (AppliedBiosystems) with Power Sybr Green PCR Master Mix (Thermo Fisher Scientific) according to the manufacturer's specifications. Transcript levels were normalized to the housekeeping genes Rps17, Actb and Oaz1 unless otherwise specified. The following primers were used in this study: Rps17 sense, 5ʹ-CGCCATTATCCCCAGCAAG-3ʹ; Rps17 antisense, 5ʹ-TGTCGG GATCCACCTCAATG-3ʹ; Oaz1 sense, 5ʹ-GTGGTGGCCTCTACATCGAG-3ʹ; Oaz1 antisense, 5ʹ-AGCAGATGAAAACGTGGTCAG-3ʹ; Actb sense, 5ʹ-CGCAGC CACTGTCGAGTC-3ʹ; Actb antisense, 5ʹ-CCTTCTGACCCATTCCCACC-3ʹ; Ifnb sense, 5ʹ-GTCCTCAACTGCTCTCCACT-3ʹ; Ifnb antisense, 5ʹ-CCT GCAACCACCACTCATTC-3ʹ; Il1rn sense, 5ʹ-CGCCCTTCTGGGAAAAGAC C-3ʹ, Il1rn antisense, 5ʹ-CCGTGGATGCCCAAGAACAC-3ʹ; Gbp5 sense, 5ʹ-TG TTCTTACTGGCCCCTGCT-3ʹ; Gbp5 antisense, 5ʹ-CCAATGAGGCACAAGGGT TC-3ʹ; Ifit3 sense, 5ʹ-AGCCCACACCCAGCTTTT-3ʹ; Ifit3 antisense, 5ʹ-CAGAGA TTCCCGGTTGACCT-3ʹ; Ch25h sense, 5ʹ-CACTCGGGCTATGACTTCCC-3ʹ; Ch25h antisense, 5ʹ-GAGTGCCCAGCATTTTGTCC-3ʹ; Irf1 sense, 5ʹ-TGAGGA AGGGAAGATAGCCG-3ʹ; Irf1 antisense, 5ʹ-TGTATGCCTATCCCAATGTCC C-3ʹ; Irgm1 sense, 5ʹ-AAAACCAGAGAGCCTCACCA-3ʹ; Irgm1 antisense, 5ʹ-AT GTTGGGGAGTAGTGGAGC-3ʹ; Gbp4 sense, 5ʹ-TGAGTACCTGGAGAATG CCCT-3ʹ; Gbp4 antisense, 5ʹ-TGGCCGAATTGGATGCTTGG-3ʹ; Stat1 sense, 5ʹ-CAGAAAAACGCTGGGAACAGA-3ʹ; Stat1 antisense, 5ʹ-CAAGCCTGGCT GGCAC-3ʹ; Gbp7 sense, 5ʹ-AGCAAGCCCAAGTTCACACT-3ʹ; Gbp7 antisense, 5ʹ-TCCGCTCTGTCAGTTCTGTG-3ʹ.
Antibody-mediated neutralization. For all antibody treatments, the schedules are indicated in the figures. All treatments were delivered by intraperitoneal injection. Mouse anti-mouse IFNAR1 (MAR1-5A3) and isotype control (GIR208, mouse anti-human IFNGR-α chain) were purchased from Leinco Technologies. Each mouse was given 500 µg per injection. Hamster anti-IL-1R1 antibody (mIL-1R-M147) was obtained from Amgen 45 . The isotype control was Ultra-LEAF purified Armenian hamster IgG isotype antibody from Biolegend (400940). Each mouse was given 200 μg per injection. Armenian hamster anti-IL-1Ra antibody was produced in-house using a previously published hybridoma line 60 . Cells were grown in Wheaton CELLine Bioreactor Flasks (Fisher Scientific) according to the manufacturer's instructions. Media in the cell compartment used ultralow IgG FBS (ThermoFisher 16250078) to minimize bovine IgG contamination during purification. Cell-free supernatant from the cell compartment was purified using protein G resin (GenScript). Resin-bound IgG was eluted using 0.1 M acetic acid, and then 1 M Tris pH 8 and 0.5 M NaCl was added (10% v/v) to neutralize the eluate. Size-exclusion and buffer exchange to PBS was performed using Amicon Ultra-4 Centrifugal Filter Units (EMD Millipore). The final product was filter sterilized and stored at −80 °C. For injections, antibody stocks were diluted in sterile PBS and each mouse received 500 µg per injection.
Statistical analysis. All survival data were analysed with a two-sided logrank test. All other data were analysed with a two-sided Mann-Whitney test unless otherwise noted. Both tests were run using GraphPad Prism 5. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. All error bars are s.e.m. and all centre bars indicate means.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Letters
Nature Microbiology
Extended Data Fig. 1 | b6 Last updated by author(s): Jun 13, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code Data collection N/A Data analysis N/A For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability N/A
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Field-collected samples N/A
Life sciences
Ethics oversight
All animal experiments complied with the regulatory standards of, and were approved by, the University of California Berkeley Institutional Animal Care and Use Committee.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
See description in methods. Briefly, perfused lungs were strained through 40μm cell strainers to obtain single cells.
Instrument
LSR Fortessa X-20 (BD) Software FlowJo Ver.10
Cell population abundance N/A
Gating strategy Cells were gated by FSC/SSC for leukocytes, single cells by FSC-A v. FSC-W. Live cells were gated as stain negative based on an unstained control. Gates were drawn with FMO (Full panel Minus One) staining as the negative control. Cells were gated for CD45+, then CD11bhi Ly6G+ for neutrophils.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
